ATRA•benzinga•
Atara Biotherapeutics Transfers Full Manufacturing Responsibility For Tabelecleucel To Pierre Fabre; Now Entitled To Receive Up To $550M In Additional Potential Milestone Payments Upon Achieving Certain Regulatory And Commercial Milestones Relating To Tab
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 4, 2025 by benzinga